Sign in

Samuel Blaichman

Director at Waystar Holding
Board

About Samuel Blaichman

Samuel Blaichman, 49, is an independent Class I director of Waystar Holding Corp., serving since April 2024. He is Managing Director and Head of Direct Private Equity at the Canada Pension Plan Investment Board (CPPIB), which he joined in 2007; prior roles include management consulting at Bain & Company and work in Corporate Finance and Assurance at PricewaterhouseCoopers. The board has affirmatively determined he is independent under Nasdaq rules; he was selected for his private equity investing experience and corporate strategy acumen.

Past Roles

OrganizationRoleTenureCommittees/Impact
Bain & CompanyManagement ConsultantNot disclosedStrategy and operations experience highlighted by board selection rationale
PricewaterhouseCoopersCorporate Finance and AssuranceNot disclosedFinance and controls background

External Roles

OrganizationRoleTenureCommittees/Impact
CPPIBManaging Director, Head of Direct Private Equity2007–presentSponsor representative; CPPIB holds 17.2% of WAY
Ascot GroupDirectorCurrentSpecialty risk-assumption organization
The Gates CorporationDirectorPastManufacturer of belts and fluid power products
Air Distribution TechnologiesDirectorPastManufacturer of air distribution/ventilation solutions
Wilton ReDirectorPastLife insurance company
Berlin PackagingDirectorPastHybrid packaging supplier

Board Governance

  • Committee assignments: Talent & Compensation Committee (members: Chair Heidi Miller; Samuel Blaichman; Priscilla Hung; John Driscoll; Ethan Waxman) and Nominating & Corporate Governance Committee (Chair Eric Liu; Samuel Blaichman; John Driscoll; Heidi Miller).
  • Independence: Board determined all directors other than the CEO are independent under Nasdaq; Blaichman qualifies.
  • Attendance: In 2024, the board met 5 times; committees met ACRC 4, TCC 5, NCGC 1; each director attended at least 75% of meetings; independent directors meet regularly in executive session.
  • Tenure/classification: Class I (Blaichman, Hung, Riefberg) stand for election to terms ending 2028; board is classified into three classes.
  • Sponsor nomination rights: CPPIB has the right to nominate one director so long as it owns ≥5%; Institutional Investors have committee nomination rights; EQT can designate the chair subject to CPPIB consent at ≥20% ownership.
  • Board size amendment: Proposal to remove the 10-director cap; while sponsors retain nomination rights, expanding board size requires consent of EQT, CPPIB, and Bain nominees.

Fixed Compensation

Component2024 Amount/TermsNotes
Annual cash retainerNot applicableCompany policy grants retainers only to non-employee directors not employed by EQT, CPPIB, or Bain; sponsor-affiliated directors are excluded.
Committee chair/member feesNot applicableSame sponsor-affiliated exclusion applies.
Meeting feesNot disclosedNo meeting fees policy disclosed; retainers cover service.
Director fees table presenceNot disclosed for Blaichman2024 director compensation table covers non-sponsor-affiliated directors and shows $— for sponsor-affiliated nominees; Blaichman is not listed.

Performance Compensation

Component2024 Grant/TermsPerformance Metrics
RSUs (annual equity retainer)Not applicableRSUs granted only to non-employee directors not employed by Institutional Investors.
Non-Employee Director Deferral PlanEligible for deferral only if receiving cash/RSUsDeferral elections create deferred stock units from cash/RSUs; settlement timing at director’s election.

Other Directorships & Interlocks

EntityRelationship to WaystarExposure
CPPIB17.2% beneficial owner; prior lender under First Lien Credit FacilityLargest principal owed to CPPIB $17.7M (2024); CPPIB exited facility in Feb 2024; $3.2M remained outstanding at YE 2024; sponsor nomination/committee rights.
Parkway PropertiesOffice lease in Houston; CPPIB owns >10%Payments of ~$0.2–0.3M annually (2022–2024).
Multiple Bain-affiliated clients/vendorsRevenues from Aveanna, Surgery Partners, Innovacare, Athena Therapy, US Renal Care; payments to Rocket Software, Fidelity Information ServicesClient receipts and vendor payments disclosed; indicates broader sponsor ecosystem engagement.

Expertise & Qualifications

  • Private equity investing leadership and direct deal execution (Head of Direct PE at CPPIB).
  • Corporate strategy, finance, and assurance experience from Bain & Company and PwC.
  • Board selection rationale emphasizes PE experience and strategic understanding.

Equity Ownership

HolderShares Beneficially Owned% OutstandingComponents within 60 days (RSUs/options)Pledging
Samuel BlaichmanNot disclosedAs of April 21, 2025, no pledging by any directors or executive officers.
  • Director stock ownership guidelines: Apply to non-employee directors not employed by EQT, CPPIB, or Bain; target minimum ownership of 3x annual cash retainer, with initial compliance due by 2027 for covered directors. Blaichman’s sponsor-affiliated status indicates exclusion from these guidelines.

Governance Assessment

  • Board effectiveness: Blaichman contributes PE and strategic expertise; active roles on Compensation and Nominating committees align with his background. Attendance thresholds met across 2024, indicating engagement.
  • Independence and alignment: Formally independent under Nasdaq rules; however, CPPIB sponsor nomination and committee placement rights create structural influence that investors should monitor.
  • Compensation and incentives: No company-paid director cash/RSUs disclosed for sponsor-affiliated directors, suggesting no direct pay from Waystar and no RSU-based performance alignment at the director level for Blaichman.
  • Related-party exposure (RED FLAG): CPPIB historical lending to Waystar under the First Lien Credit Facility and CPPIB-affiliated Parkway lease are related party transactions; while disclosed and routine in sponsor-backed companies, they require continued oversight for arm’s-length terms.
  • Sponsor influence risk (RED FLAG): Board size changes and chair designation require sponsor consent; CPPIB, EQT, and Bain retain nomination and committee rights, potentially constraining governance flexibility until ownership thresholds change.
  • Ownership alignment: No personal beneficial holdings disclosed for Blaichman; guidelines exclude sponsor-affiliated directors—alignment is primarily via CPPIB’s 17.2% stake rather than individual holdings.

Overall signal: Competency and committee engagement are positives; sponsor rights and related-party transactions represent manageable but material governance considerations that can affect investor confidence, warranting continued monitoring of independence practices, committee decision-making, and arm’s-length validations.